The Centers for Disease Control and Prevention issued a national Health Alert Network advisory on Aug. 11 warning that patients taking B cell-depleting or B cell-modulating medications, particularly the anti-CD20 monoclonal antibodies used for lymphoma, multiple sclerosis, and several autoimmune conditions, face unusually severe outcomes if they contract a mosquito- or tick-borne virus that reaches the brain.
The figure at the center of the advisory is stark. Among published case reports of arboviral neuroinvasive disease in patients on anti-CD20 monoclonal antibodies, overall mortality was approximately 40 percent, and most survivors experienced long-term neurologic damage, the CDC said. West Nile virus was the most commonly reported virus.
That number requires careful reading. It comes from published case reports, not a population survey, and case reports tend to skew toward severe outcomes because milder illnesses often go unreported. It describes what happened to patients who were sick enough to be written up in the medical literature. It is not the odds facing any individual patient who takes one of these medications.
The Medications and the Patients Involved
The drug class is widely used. Anti-CD20 monoclonal antibodies approved in the United States include rituximab and its biosimilars, ocrelizumab, ofatumumab, ublituximab, obinutuzumab, and ibritumomab tiuxetan. They are prescribed for B-cell cancers, for multiple sclerosis, for rheumatoid arthritis and other autoimmune diseases, and to prevent transplant rejection. The advisory also covers other agents that deplete B cells, such as anti-CD38 antibodies, or modulate B cell function, such as B cell activating factor inhibitors.
These drugs work by depleting or suppressing B cells, the immune cells that produce antibodies. That is precisely why an arbovirus infection can turn severe. Patients on these therapies may mount no antibody response to a new infection and can experience prolonged viremia and an illness the body struggles to clear.
The CDC also described a newer and unsettling pattern. In recent years, at least five patients receiving rituximab developed a chronic, neurodegenerative encephalitis that unfolded over months to years after infection with an orthobunyavirus such as Jamestown Canyon, Cache Valley, or Potosi virus. All five died. Diagnosis was delayed in each case because the infection went unrecognized, and identifying the pathogen required specialized testing.
Timing Explains the Urgency
The advisory landed in the middle of an active transmission season. The CDC noted that the United States had an early and strong start to this year's West Nile virus season, with many weeks of arbovirus transmission remaining.
National case counts are tracked through ArboNET, the surveillance system managed by the CDC and state health departments. Those figures are preliminary, are refreshed every one to two weeks through the summer and fall, and lag actual illness due to reporting delays, so state and local health departments often have more current information. August and September are historically the heaviest months for West Nile transmission across most of the continental United States, which means the highest-risk weeks for the patients this advisory concerns are happening now.
There is no human vaccine for arboviral diseases endemic to the United States, no approved antiviral treatment, and no preventive drug. Avoiding bites is the entire toolkit.
Diagnosis Is the Practical Problem
The advisory's most consequential clinical instruction concerns testing. Standard arboviral diagnosis relies on detecting virus-specific IgM antibodies in blood or spinal fluid. A patient whose B cells have been depleted may never produce those antibodies, so a routine serologic test can come back negative even if they are actively infected.
The CDC advised clinicians to preferentially order molecular testing, meaning virus-specific RT-PCR or metagenomic next-generation sequencing, when arboviral infection is suspected in a patient receiving B-cell depleting monoclonal antibodies. The agency told state laboratories that whole blood and urine specimens are more sensitive than serum or spinal fluid for West Nile PCR, while noting that serum and spinal fluid are still needed for the serologic testing used to rule out infection when PCR is negative. Clinicians are directed to contact state or local health departments for guidance on the right specimen and the right laboratory, and the agency maintains a diagnostic testing algorithm for suspected West Nile virus disease.
The agency also warned that these patients may not follow the seasonal script. Incubation can be prolonged, the illness course can be atypical, and symptoms may appear outside the usual May through November window when mosquitoes and ticks are active. A neurologic illness in February in a patient on rituximab still warrants a full exposure and travel history.
The underlying evidence base is not new. A review published in Clinical Infectious Diseases identified 21 patients on recent rituximab therapy who developed arboviral disease. All had neuroinvasive disease; diagnosis required molecular testing in 20 of the 21; the median illness duration was 36 days; and 15 of the 19 patients with a reported outcome died. The authors cautioned that the small number of patients and the potential for reporting bias mean the series may not represent typical arboviral disease in patients on rituximab. The CDC advisory extends that concern to the broader class of B-cell-depleting and B-cell-modulating drugs.
Reasonable Steps for Patients and Families
The CDC's guidance for the public is deliberately modest, and no one taking these medications should stop or alter treatment because of this advisory. These drugs treat serious conditions, and the decision belongs to the prescribing clinician.
What the agency asks is that patients on immunosuppressive therapy know they may face a higher risk of severe illness from infections, including arboviral ones, and that they take bite prevention seriously. That means using EPA-registered insect repellent, wearing loose-fitting long-sleeved shirts and pants outdoors, treating clothing and gear with products containing 0.5 percent permethrin, using screens on windows and doors or air conditioning, avoiding wooded and brushy areas with high grass and leaf litter, and checking clothing, body, gear and pets for ticks after coming inside. The full prevention guidance is on the CDC site.
Patients should notify a clinician about concerning changes such as persistent headache, fever, body aches, weakness, loss of balance, or confusion, and should mention recent travel, mosquito or tick exposure, and the medications they take. That last detail is the one most likely to change how a doctor tests.
Households caring for a relative on these drugs can help by handling yard drainage, checking window screens, and keeping repellent accessible, since the person at risk may be the one least able to manage those tasks.
The CDC has also published clinical guidance for immunocompromised patients along with patient awareness materials that clinicians can share during infusion visits.
What remains unknown is the actual population-level risk. Case reports cannot establish how often patients on these medications get infected, how many recover without hospitalization, or which of the several drugs in the class carries the greatest exposure. The CDC has not published an incidence estimate, and the advisory does not claim one.
Key Questions Answered
What did the CDC announce? On Aug. 11, the agency issued a Health Alert Network health advisory warning that patients on B-cell depleting or B-cell modulating medications face severe outcomes from arboviral neuroinvasive disease, citing approximately 40 percent mortality across published case reports.
Does 40 percent mean four in ten patients on these drugs will die? No. The figure describes outcomes among patients severe enough to appear in published case reports. It is not an incidence or a population risk estimate, and milder cases are underrepresented in that literature.
Which medications does this involve? Anti-CD20 monoclonal antibodies including rituximab and biosimilars, ocrelizumab, ofatumumab, ublituximab, obinutuzumab and ibritumomab tiuxetan. The advisory also references other agents that deplete or modulate B cell function.
Should anyone stop taking these medications? No. The CDC does not recommend stopping or changing therapy. Any decision about these drugs belongs with the prescribing clinician.
What symptoms should prompt a call to a doctor? Persistent headache, fever, body aches, weakness, loss of balance, or confusion. Patients should mention their medications and any mosquito or tick exposure, because that information changes which tests the clinician orders.
Why can standard testing miss the infection? Routine arboviral testing looks for antibodies. Patients with depleted B cells may not produce them, so the CDC advises molecular testing, such as RT-PCR or metagenomic sequencing, instead.
How do people avoid infection? There is no vaccine and no antiviral for the arboviruses endemic to the United States. Prevention means avoiding mosquito and tick bites through repellent, protective clothing, permethrin-treated gear, intact window screens, and tick checks after time outdoors.
